Jubilant Pharmova Limited (JUBLPHARMA)
ISIN: - Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
345.6
1.8(0.52%)

Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India.

Pricing Updates

TODAY'S HIGH

348.85

TODAY'S LOW

343.8

52 WEEK HIGH

677.85

52 WEEK LOW

281.8

Major Holders

% of Shares Held by
All Insider

58.78%

% of Shares Held by
Institutions

15.69%

% of Float Held by
Institutions

38.07%

Number of Institutions
Holding Shares

32

Company Overview

MARKET CAP

5504.75 Cr.

ETERPRISE VALUE

7771.72 Cr.

NO. OF SHARES

15.92 Cr.

BOOK VALUE

334.029

DIV. YIELD

5%

DEBT

3191.99 Cr.

GROSS PROFIT

4642.16 Cr.

CASH

984.24 Cr.

REVENUE

5947.22 Cr.

REVENUE/SHARE

373.674

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments212.08 Cr.-228.83 Cr.216.08 Cr.-362.39 Cr.
Change To Liabilities-42.71 Cr.228.25 Cr.-25.11 Cr.-112.39 Cr.
Total cashflows from Investing Activities-380.37 Cr.-739.01 Cr.-327 Cr.-1011.83 Cr.
Net Borrowings182.39 Cr.-1405.61 Cr.-572.77 Cr.661.61 Cr.
Total Cash from Financing Activities-32.60 Cr.-1709.38 Cr.-1050.37 Cr.657.42 Cr.
Other Liabilities0000
Total Assets0026.20 Lakhs265.86 Cr.
Net Income413.94 Cr.835.86 Cr.898.24 Cr.574.45 Cr.
Change in Cash481.86 Cr.-728.85 Cr.225.41 Cr.761.22 Cr.
Effect of Exchange Rate57.29 Cr.12.25 Cr.59.85 Cr.-5.88 Cr.
Total Cash from Operating Activities837.54 Cr.1784.26 Cr.1542.93 Cr.1121.51 Cr.
Depreciation381.70 Cr.323.36 Cr.309.46 Cr.271.63 Cr.
Other Cashflows from Investing Activities4.02 Cr.4.11 Cr.24.53 Cr.8.85 Cr.
Dividends Paid-80.05 Cr.-1.47 Cr.-151.29 Cr.-54.58 Cr.
Change to Inventory-95.65 Cr.134.32 Cr.-374.32 Cr.16.68 Cr.
Change to Account Receivables-39.93 Cr.-112.68 Cr.219.77 Cr.-204.81 Cr.
Other Cashflows from Financing Activities-134.94 Cr.-292.23 Cr.-326.56 Cr.-215.47 Cr.
Change to Net Income220.19 Cr.375.13 Cr.514.90 Cr.487.28 Cr.
Capital Expenditures-599.99 Cr.-527.49 Cr.-574.15 Cr.-655.92 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax630.45 Cr.871.07 Cr.1012.87 Cr.903.81 Cr.
Minority Interest-2.16 Cr.3.10 Lakhs3.10 Lakhs9.90 Lakhs
Net Income774.63 Cr.1144.25 Cr.1238.72 Cr.1392.65 Cr.
Selling General Administrative2043.39 Cr.1943.96 Cr.1884.34 Cr.2009.33 Cr.
Gross Profit4642.16 Cr.4562.52 Cr.4520.60 Cr.5588.97 Cr.
Ebit774.63 Cr.1144.25 Cr.1238.72 Cr.1392.65 Cr.
Operating Income774.63 Cr.1144.25 Cr.1238.72 Cr.1392.65 Cr.
Other Operating Expenses1442.44 Cr.1150.94 Cr.1088.07 Cr.1826.69 Cr.
Interest Expense-145.49 Cr.-173.35 Cr.-188.43 Cr.-206.02 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense217.43 Cr.297.21 Cr.335.10 Cr.326.80 Cr.
Total Revenue6130.16 Cr.6098.53 Cr.5975.78 Cr.9110.81 Cr.
Total Operating Expenses5355.53 Cr.4954.28 Cr.4737.05 Cr.7718.16 Cr.
Cost of Revenue1488 Cr.1536.01 Cr.1455.18 Cr.3521.84 Cr.
Total Other Income Expense Net-144.18 Cr.-273.17 Cr.-225.85 Cr.-488.83 Cr.
Discontinued Operations0261.75 Cr.220.47 Cr.220.47 Cr.
Net Income from Continuous Ops.413.02 Cr.573.85 Cr.677.77 Cr.577 Cr.
Net Income Applicable to Common Shares413.94 Cr.835.86 Cr.898.24 Cr.574.45 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets926.32 Cr.800.58 Cr.731.41 Cr.703.05 Cr.
Capital Surplus00587.25 Cr.587.14 Cr.
Total Liabilities4674.47 Cr.4176.59 Cr.6917.77 Cr.6659.48 Cr.
Stock Holder Equity5318.56 Cr.4741.48 Cr.5603.88 Cr.4808.91 Cr.
Minority Interest-2.16 Cr.3.10 Lakhs09.90 Lakhs
Other Liabilities508.30 Cr.173.56 Cr.255.46 Cr.170.43 Cr.
Total Assets9990.87 Cr.8918.11 Cr.12521.65 Cr.11468.50 Cr.
Common Stock15.92 Cr.15.92 Cr.15.92 Cr.15.92 Cr.
Retained Earnings04318.69 Cr.4585.24 Cr.3713.54 Cr.
Other Liabilities406.44 Cr.368.33 Cr.422.94 Cr.326.87 Cr.
Good Will2242.75 Cr.2129.96 Cr.2089.46 Cr.1958.93 Cr.
Treasury Stock5302.64 Cr.406.85 Cr.415.45 Cr.492.30 Cr.
Other Assets264.86 Cr.218.85 Cr.305.57 Cr.218.79 Cr.
Cash984.24 Cr.501.95 Cr.1230.81 Cr.1005.39 Cr.
Current Liabilities1591.60 Cr.1048.83 Cr.2619.01 Cr.2089.72 Cr.
Long Term Asset Charges161.27 Cr.154.71 Cr.211.24 Cr.149.54 Cr.
Short Long Term Debt00238.64 Cr.88.45 Cr.
Other Stockholder Equity5302.64 Cr.406.85 Cr.415.45 Cr.492.30 Cr.
Property Plant Equipment2791.11 Cr.2575.19 Cr.4287.48 Cr.3887.81 Cr.
Total Cur. Assets3509.19 Cr.2952.50 Cr.5038.34 Cr.4584.79 Cr.
Long Term Investments256.64 Cr.241.01 Cr.69.36 Cr.115.10 Cr.
Net Tangible Assets2149.49 Cr.1810.93 Cr.2783 Cr.2146.92 Cr.
Short Term Investments0187.47 Cr.187.39 Cr.377.03 Cr.
Net Receivables929.57 Cr.1029.65 Cr.1644.17 Cr.1653.10 Cr.
Long Term Debt2464.24 Cr.2563.97 Cr.3739.68 Cr.4231.80 Cr.
Inventory1254.87 Cr.1142.85 Cr.1879.22 Cr.1449.15 Cr.
Accounts Payable567.74 Cr.520.48 Cr.1090.26 Cr.1020.12 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account